<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920931</url>
  </required_header>
  <id_info>
    <org_study_id>BR-TND-CT-101</org_study_id>
    <nct_id>NCT02920931</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and&#xD;
      Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir&#xD;
      Disoproxil Fumarate) in Healthy Male Volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration(Cmax) of Tenofovir</measure>
    <time_frame>0~72 hour after medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve(AUCt) of Tenofovir</measure>
    <time_frame>0~72 hour after medication</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hepatitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>st period: Tenofovir disoproxil fumarate&#xD;
nd period: Tenofovir Disoproxil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>st period: Tenofovir disoproxil&#xD;
nd period: Tenofovir Disoproxil fumarate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subject, aged 19- 45 years at screening.&#xD;
&#xD;
          2. Body weight of ≥ 55 kg and within ± 20% of ideal body weight (IBW)(kg) = {height (cm)&#xD;
             - 100} * 0.9&#xD;
&#xD;
          3. No morbid symptom or sign, based on physical examination, with no innate or chronic&#xD;
             disease.&#xD;
&#xD;
          4. Subject that is considered appropriate for participating in the study by an&#xD;
             investigator, based on clinical laboratory test (hematology, clinical chemistry,&#xD;
             urinalysis) that is performed according to the characteristics of investigational&#xD;
             drugs.&#xD;
&#xD;
          5. Subjects must be able to listen to and understand the detailed statement of informed&#xD;
             consent, and willing to decide to participate in the study, follow the study&#xD;
             directions and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A clinically significant disease or history in hepatobiliary system, kidney, digestive&#xD;
             system, respiratory system, hemato-oncological system, endocrine system,&#xD;
             neuro-psychiatric system, musculo-skeletal system, immune system,&#xD;
             otorhinolaryngological system or cardiovascular system.&#xD;
&#xD;
          2. A history of gastrointestinal system disorder(i.e, Crohn's disease, ulcer, acute or&#xD;
             chronic pancreatitis) or surgery (excluding simple appendectomy or herniorrhaphy) that&#xD;
             may affect absorption of investigational drugs.&#xD;
&#xD;
          3. A history of hypersensitivity to investigational drugs and its additives or clinically&#xD;
             significant hypersensitivity to any other drug.&#xD;
&#xD;
          4. Galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption and&#xD;
             any other hereditary disorder.&#xD;
&#xD;
          5. Vital sign measured in sitting position meets any one of following results; systolic&#xD;
             blood pressure &gt; 140 mmHg or &lt;100 mmHg, diastolic blood pressure &gt; 90 mmHg or &lt;60&#xD;
             mmHg, pulse ≥ 100 times/min.&#xD;
&#xD;
          6. Aspartate aminotransferase(AST) or Alanine aminotransaminase(ALT) &gt; 2 times upper&#xD;
             normal limit, or Total bilirubin &gt; 2 times upper normal limit.&#xD;
&#xD;
          7. Renal disorder (Creatinine clearance &lt; 50 mL/min, calculated by Cockcroft-Gault&#xD;
             formula)&#xD;
&#xD;
          8. Positive in serologic tests (RPR Ab(VDRL), HBsAg, hepatitis C virus (HCV) Ab, anti&#xD;
             HIV(AIDS))&#xD;
&#xD;
          9. History of drug abuse, or positive in drug screening test.&#xD;
&#xD;
         10. Use of inducer or inhibitor of metabolic enzymes for drugs like barbiturate.&#xD;
&#xD;
         11. Use of any prescribed drugs or herbal remedies within 2 weeks, or use of any&#xD;
             over-the-counter medication within 1 week prior to the first administration of&#xD;
             investigational drug, and this will affect this study or the safety of the subjects at&#xD;
             discretion of study investigator.&#xD;
&#xD;
         12. Participation in another clinical trial or a bioequivalent study within 3 months prior&#xD;
             to the first administration of investigational drug (The finish time of previous study&#xD;
             is the day of the last administration of study drug)&#xD;
&#xD;
         13. Whole blood donation within 2 months or component donation within 1 month, prior to&#xD;
             the first administration of investigational drug, or transfusion within 1 month prior&#xD;
             to the first administration of investigational drug.&#xD;
&#xD;
         14. Prolonged excessive alcohol consumption (&gt;21 units/week, 1 unit=10g of pure alcohol),&#xD;
             or subjects who can not abstain from drinking from 24 hours prior to hospitalization&#xD;
             until the discharge.&#xD;
&#xD;
         15. Smoking more than 10 cigarettes per day, excessive caffeine consumption (example:&#xD;
             instant coffee &gt; 5 cups/day)&#xD;
&#xD;
         16. Subjects planning to get a dental treatment(tooth extraction, orthodontic treatment,&#xD;
             endodontic treatment etc) and a selective surgery(aesthetic surgery, LASIK, LASEK etc)&#xD;
             during the period from informed consent form(ICF) to post-study visit, which is&#xD;
             impossible to be postponed.&#xD;
&#xD;
         17. Subjects who are judged to be inappropriate for this study by investigators according&#xD;
             to other reasons including clinical lab test result&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jang Hee Hong, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ChungNam university hospital</name>
      <address>
        <city>ChungNam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

